Researchers at Mass General Brigham have demonstrated that older U.S. veterans who initiated statin therapy were significantly less likely to develop frailty over time, suggesting that the cholesterol-lowering medications may have healthy aging benefits beyond cardiovascular disease prevention. Results are published in the European Heart Journal.
Mass General BrighamJun 9 2026 Research ers at Mass General Brigham have demonstrated that older U.S. veterans who initiated statin therapy were significantly less likely to develop frailty over time, suggesting that the cholesterol-lowering medications may have healthy aging benefits beyond cardiovascular disease prevention.
Results are published in the European Heart Journal. There are currently no approved medications specifically to prevent frailty. Our findings suggest that statins may offer an important opportunity to reduce the risk of frailty and help people preserve their health and independence as they age.
" Saadia Qazi, DO, MPH, MSc, lead author of the study and cardiologist at VA Boston and in the Division of Aging in Mass General Brigham's Department of Medicine Frailty is characterized by muscle loss, fatigue, slow walking speed, and low levels of activity. Older adults who are categorized as frail by a health care provider are more likely to experience a dramatic decline in function after a minor illness or injury.
As older adults in the U.S. experience a high rate of frailty, there's a growing need to identify prevention and treatment strategies for it. The study authors explain that statins have anti-inflammatory effects in addition to lowering cholesterol, and this may help slow processes associated with biological aging and functional decline.
In a retrospective cohort study, Qazi and colleagues analyzed Medicare and Medicaid data from 987,301 U.S. veterans receiving care through the Veterans Affairs health system between 2002 and 2018 and assessed the development of frailty in those who did not take statins and those who did. At the beginning of the analysis period, all veterans were aged 67 years and older, considered to be non-frail, and were not taking statins.
Frailty was assessed using a validated 31-item Veterans Affairs Frailty Index. Related StoriesOver an average follow-up period of 5.3 years, 290,729 veterans started statin therapies and more than 636,000 veterans developed frailty. After adjusting for many differences between participants, including body mass index, sex, race, smoking status, cardiovascular disease, cancer, and other factors,statin initiation was associated with a 24% lower risk of developing frailty compared with non-statin use.
The association between statin use and reduced risk of frailty was consistent across many subgroups, including older age groups and people with diabetes, cardiovascular disease, arthritis, or dementia. The association was also found among those who were "pre-frail," showing some early signs of frailty at the beginning of the study. This finding suggests that statins may be beneficial in preventing frailty even if they're not taken years before frailty starts.
"While randomized trials are needed, these observational findings suggest a potential role for statins in preventing frailty," said senior author Ariela Orkaby, MD, MPH, a geriatrician at VA Boston and Mass General Brigham. "We know that frailty and heart disease share underlying mechanisms. Our study suggests that targeting those mechanisms could help prevent both outcomes.
" Source:Mass General Brigham Journal reference:Qazi, S., et al. Statins and survival free of incident frailty among older US veterans, European Heart Journal. DOI: 10.1093/eurheartj/ehag451. https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag451/8701261
Please follow us on Google to support us Aging Cardiovascular Disease Cholesterol Fatigue Health Care Heart Medicine Muscle Research Therapy Veterans Affairs Walking
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Researchers develop compound 10 to slow Alzheimer's disease progressionResearchers from ETH Zurich have developed an active ingredient that slows down the progression of typical Alzheimer’s symptoms in mice. This new substance protects nerve cells and could in future alleviate the suffering of Alzheimer’s patients. The active ingredient also shows anti-aging effects.
Read more »
UK boffin bait lands 18 international researchersGlobal Talent visa program aims to draw in dissatisfied scientists from countries including the US
Read more »
Researchers induce sleep-like brain activity to reverse memory lossBy inducing specific patterns of activity in small portions of the brain in awake mice, researchers supported by the National Institutes of Health (NIH) have triggered a recalibration of neural connections that normally only occurs during sleep.
Read more »
Researchers find flaw in AI models for sepsis treatmentAI is already boosting positive outcomes in healthcare and holds promise for delivering many more. It is important, however, that deployment of AI tools - especially in a life-or-death healthcare setting - proceeds at a thoughtful and measured pace, cautions Shengpu Tang, assistant professor of computer science at Emory University.
Read more »